Lifestyle Modification and Liraglutide
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 21 - 70 |
| Updated: | 2/22/2019 |
| Start Date: | September 2016 |
| End Date: | December 2018 |
Combining Lifestyle Modification and Liraglutide to Improve Weight Loss and Health Outcomes
This is a 52 week, single center, open-labeled, randomized controlled trial.
A total of 150 subjects with obesity, who are free of types 1 and 2 diabetes, as well as
contraindications to weight loss, will be randomly assigned to one of three treatment groups:
1) lifestyle counseling, as currently recommended by the Centers for Medicare and Medicaid
Services (CMS) (i.e., CMS-Alone); 2) CMS lifestyle counseling plus liraglutide (i.e.,
CMS-Liraglutide); or 3) CMS-Liraglutide plus a portion-controlled diet (i.e., Multi-Component
Intervention).
Subjects in all three groups will have 14 brief (15 minute) lifestyle counseling visits the
first 24 weeks, followed by monthly visits in weeks 25-52. This is the schedule and duration
of counseling visits recommended by CMS. Counseling sessions will be delivered by a
physician, nurse practitioner or registered dietitian (RD) working in consultation with the
former providers.
Subjects in all three groups also will have brief physician visits at weeks 1, 4, 8, 16, 24,
36, and 52 (total of 7 visits). These visits are needed for subjects in both liraglutide
groups to monitor their response to the medication. These visits are included for subjects in
CMS-Alone to match the intensity of medical care provided the two other groups.
The primary outcome is % reduction in initial body weight, as measured from randomization to
week 52. Secondary outcomes include the proportion of participants who at week 52 lose >5%,
>10%, and >15% of initial weight, as well as % reduction in weight at week 24 and the
proportion of participants who meet the three categorical weight losses at this time. The
secondary efficacy measures include changes (from randomization to week 52) in cardiovascular
disease (CVD) risk factors, glycemic control, mood, quality of life, eating behavior,
appetite, sleep, and satisfaction with weight loss.
Safety endpoints will include physical examination, adverse events (AEs), standard laboratory
tests, and mental health assessed by the Columbia Suicidality Severity Rating Scale (C-SSRS)
and Patient Health Questionnaire (PHQ-9).
Statistical Analysis. Using a sample size equation for longitudinal clustered samples, a
randomization sample of 50 subjects in CMS-Alone, 50 in CMS-Liraglutide, and 50 in the
Multi-Component Intervention provides >80% power to detect the two primary contrasts to be
statistically significant. This estimate allows for 20% attrition during the 52-week trial,
resulting in approximately 40 treatment completers per group. The ITT longitudinal
statistical design will further improve power by allowing the inclusion of available data for
non-completers and the adjustment of possible variance reducing baseline covariates.
A total of 150 subjects with obesity, who are free of types 1 and 2 diabetes, as well as
contraindications to weight loss, will be randomly assigned to one of three treatment groups:
1) lifestyle counseling, as currently recommended by the Centers for Medicare and Medicaid
Services (CMS) (i.e., CMS-Alone); 2) CMS lifestyle counseling plus liraglutide (i.e.,
CMS-Liraglutide); or 3) CMS-Liraglutide plus a portion-controlled diet (i.e., Multi-Component
Intervention).
Subjects in all three groups will have 14 brief (15 minute) lifestyle counseling visits the
first 24 weeks, followed by monthly visits in weeks 25-52. This is the schedule and duration
of counseling visits recommended by CMS. Counseling sessions will be delivered by a
physician, nurse practitioner or registered dietitian (RD) working in consultation with the
former providers.
Subjects in all three groups also will have brief physician visits at weeks 1, 4, 8, 16, 24,
36, and 52 (total of 7 visits). These visits are needed for subjects in both liraglutide
groups to monitor their response to the medication. These visits are included for subjects in
CMS-Alone to match the intensity of medical care provided the two other groups.
The primary outcome is % reduction in initial body weight, as measured from randomization to
week 52. Secondary outcomes include the proportion of participants who at week 52 lose >5%,
>10%, and >15% of initial weight, as well as % reduction in weight at week 24 and the
proportion of participants who meet the three categorical weight losses at this time. The
secondary efficacy measures include changes (from randomization to week 52) in cardiovascular
disease (CVD) risk factors, glycemic control, mood, quality of life, eating behavior,
appetite, sleep, and satisfaction with weight loss.
Safety endpoints will include physical examination, adverse events (AEs), standard laboratory
tests, and mental health assessed by the Columbia Suicidality Severity Rating Scale (C-SSRS)
and Patient Health Questionnaire (PHQ-9).
Statistical Analysis. Using a sample size equation for longitudinal clustered samples, a
randomization sample of 50 subjects in CMS-Alone, 50 in CMS-Liraglutide, and 50 in the
Multi-Component Intervention provides >80% power to detect the two primary contrasts to be
statistically significant. This estimate allows for 20% attrition during the 52-week trial,
resulting in approximately 40 treatment completers per group. The ITT longitudinal
statistical design will further improve power by allowing the inclusion of available data for
non-completers and the adjustment of possible variance reducing baseline covariates.
The addendum to the original 52-week trial, is a 12-week, single center, randomized
placebo-controlled, parallel group designed trial. This 12-week extension study is separate
from the original 52-week trial and will not affect the outcome or analysis of the 52-week,
3-arm trial.
Participants and investigators will be masked to participants' assignment to phentermine 15
mg/d versus placebo. Participants in both groups will receive liraglutide in an open-label
manner.
We anticipate that 23 (of 50) participants from the original CMS-Liraglutide group and 23 (of
50) from the Multi-Component Intervention will be eligible to participate in the extension
study and will elect to do so. We anticipate that 20 participants in each group will complete
the 12-week extension study and that those who receive liraglutide 3.0 mg plus phentermine
15.0 mg/d will lose, from randomization to week 12, 3.5+3.5% of initial weight, compared with
0.0+0.5% for those assigned to liraglutide plus placebo.
All participants in the extension study will meet with a physician or nurse practitioner at
randomization (week 0) and at weeks 2, 4, 8 and 12. On each occasion they will review
patients' blood pressure and pulse, assess suicidal ideation, and record and respond
appropriately to reports of changes in physical health. As during the 1-year prior trial,
brief lifestyle counseling (15 min) will provided at monthly visits (excluding week 2) by the
physician or nurse practitioner or by a registered dietitian or behavioral psychologist,
working under their supervision. The lifestyle intervention will be the same as that provided
during the last 6 months of both the CMS-Liraglutide and Multi-Component interventions.
Following the 12-week randomized trial, phentermine (or placebo) will be terminated, and all
participants will continue to receive liraglutide 3.0 mg/d for an additional 8 weeks (i.e.,
weeks 12-20) and have lifestyle counseling and medical assessments at weeks 16 and 20.
Liraglutide 3.0 mg/d will be terminated at week 20, and participants will have a final safety
assessment at week 24.
The primary endpoint of the 12-week extension trial is change in body weight (i.e., %
reduction in randomization weight), as measured from randomization (week 0) to week 12.
Secondary endpoints include the proportion of subjects who lose > 5% or > 10% of initial
weight from randomization to week 12, as well as changes from randomization to week 12 in
cardiovascular disease (CVD) risk factors (i.e, blood pressure, triglycerides, LDL and HDL
cholesterol, and waist circumference), glycemic control (i.e., fasting blood sugar), mood
(PHQ-9), quality of life (i.e, SF-36 and IWQOL-Lite), eating behavior (i.e., Eating
Inventory, Eating Disorder Examination-Questionnaire, and Yale Food Addiction Scale),
appetite (i.e., visual analogue scales), sleep (i.e., Pittsburgh Sleep Quality Index), and
weight loss satisfaction. (All of these measures were administered in the original 1-year
trial.)
Safety endpoints will include physical examination, adverse events (AEs), standard laboratory
tests, and mental health assessed by the Columbia Suicidality Severity Rating Scale (C-SSRS)
and Patient Health Questionnaire (PHQ-9).
All data analyses will proceed using the same principles and methods used in the original
protocol.
placebo-controlled, parallel group designed trial. This 12-week extension study is separate
from the original 52-week trial and will not affect the outcome or analysis of the 52-week,
3-arm trial.
Participants and investigators will be masked to participants' assignment to phentermine 15
mg/d versus placebo. Participants in both groups will receive liraglutide in an open-label
manner.
We anticipate that 23 (of 50) participants from the original CMS-Liraglutide group and 23 (of
50) from the Multi-Component Intervention will be eligible to participate in the extension
study and will elect to do so. We anticipate that 20 participants in each group will complete
the 12-week extension study and that those who receive liraglutide 3.0 mg plus phentermine
15.0 mg/d will lose, from randomization to week 12, 3.5+3.5% of initial weight, compared with
0.0+0.5% for those assigned to liraglutide plus placebo.
All participants in the extension study will meet with a physician or nurse practitioner at
randomization (week 0) and at weeks 2, 4, 8 and 12. On each occasion they will review
patients' blood pressure and pulse, assess suicidal ideation, and record and respond
appropriately to reports of changes in physical health. As during the 1-year prior trial,
brief lifestyle counseling (15 min) will provided at monthly visits (excluding week 2) by the
physician or nurse practitioner or by a registered dietitian or behavioral psychologist,
working under their supervision. The lifestyle intervention will be the same as that provided
during the last 6 months of both the CMS-Liraglutide and Multi-Component interventions.
Following the 12-week randomized trial, phentermine (or placebo) will be terminated, and all
participants will continue to receive liraglutide 3.0 mg/d for an additional 8 weeks (i.e.,
weeks 12-20) and have lifestyle counseling and medical assessments at weeks 16 and 20.
Liraglutide 3.0 mg/d will be terminated at week 20, and participants will have a final safety
assessment at week 24.
The primary endpoint of the 12-week extension trial is change in body weight (i.e., %
reduction in randomization weight), as measured from randomization (week 0) to week 12.
Secondary endpoints include the proportion of subjects who lose > 5% or > 10% of initial
weight from randomization to week 12, as well as changes from randomization to week 12 in
cardiovascular disease (CVD) risk factors (i.e, blood pressure, triglycerides, LDL and HDL
cholesterol, and waist circumference), glycemic control (i.e., fasting blood sugar), mood
(PHQ-9), quality of life (i.e, SF-36 and IWQOL-Lite), eating behavior (i.e., Eating
Inventory, Eating Disorder Examination-Questionnaire, and Yale Food Addiction Scale),
appetite (i.e., visual analogue scales), sleep (i.e., Pittsburgh Sleep Quality Index), and
weight loss satisfaction. (All of these measures were administered in the original 1-year
trial.)
Safety endpoints will include physical examination, adverse events (AEs), standard laboratory
tests, and mental health assessed by the Columbia Suicidality Severity Rating Scale (C-SSRS)
and Patient Health Questionnaire (PHQ-9).
All data analyses will proceed using the same principles and methods used in the original
protocol.
Inclusion Criteria:
1. Participants must have a BMI ≥ 30 and ≤ 55 kg/m²
2. Age ≥ 21 years and ≤ 70 years
3. Eligible female patients will be:
- non-pregnant, evidenced by a negative urine dipstick pregnancy test
- non-lactating
- surgically sterile or postmenopausal, or they will agree to continue to use an
accepted method of birth control during the study
4. Ability to provide informed consent before any trial-related activities
5. Participants must:
- have a primary care provider (PCP) who is responsible for providing routine care
- have a reliable telephone service with which to communicate with study staff
- understand and be willing to comply with all study-related procedures and agree
to participate in the study by giving written informed consent
- plan to remain in the Philadelphia area for the next 18 months
Exclusion Criteria:
1. Pregnant or nursing, or plans to become pregnant in the next 18 months, or not using
adequate contraceptive measures
2. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia
syndrome type 2
3. Uncontrolled hypertension (systolic blood pressure ≥ 160 mm Hg or diastolic blood
pressure ≥ 100 mm Hg)
4. Type 1 diabetes
5. Type 2 diabetes
6. A fasting glucose ≥ 126 mg/dl (on second assessment after first elevated value)
7. Recent history of cardiovascular disease (e.g., myocardial infarction or stroke within
the past 6 months), congestive heart failure, or heart block greater than first degree
8. Clinically significant hepatic or renal disease
9. Thyroid disease, not controlled
10. History of malignancy (except for non-melanoma skin cancer) in past 5 years
11. Current major depressive episode, active suicidal ideation, or history of suicide
attempts
12. Psychiatric hospitalization within the past 6 months
13. Self-reported alcohol or substance abuse within the past 12 months, including at-risk
drinking (current consumption of ≥ 14 alcoholic drinks per week)
14. Use in past 3 months of medications known to induce significant weight loss (i.e.,
prescription weight loss medications) or weight gain (e.g., chronic use of oral
steroids, second generation antipsychotics)
15. Loss of ≥ 10 lb of body weight within the past 3 months
16. History of (or plans for) bariatric surgery
17. Inability to walk 5 blocks comfortably or engage in some other form of aerobic
activity (e.g., swimming)
18. Known or suspected allergy to trial medication(s), excipients, or related products
19. Hypersensitivity to liraglutide or any product components
20. The receipt of any investigational drug within 6 months prior to this trial
21. Previous participation in this trial (e.g., randomized and failed to participate)
22. History of pancreatitis
23. Subjects will be included/excluded according to the latest updated US PI.
12-Week Extension Trial:
Inclusion Criteria
Inclusion criteria are those described for the original 1-year trial (enumerated above).
The principal exception from these criteria is that participants will only be required to
have a BMI > 27 kg/m2, with or without co-morbidities, to be eligible to participate in the
extension study. All participants will have met BMI inclusion criteria when they initiated
the use of liraglutide and now will use it, potentially with phentermine 15 mg/d, to
facilitate to the maintenance of lost weight. (Liraglutide is approved for chronic weight
management, including following successful weight loss.) We do not wish to enroll
participants with a BMI < 27 kg/m2 because of the possibility that they could reduce
substantially below a BMI of 24.9 kg/m2, the upper limit of "normal" weight.
Exclusion Criteria:
Exclusion criteria will include those listed in the original protocol, including those
specific to the use of liraglutide 3.0 mg/d (e.g., family history of medullary thyroid
cancer).
Additional exclusion criteria added to the 12-week extension study are specific to the use
of phentermine 15 mg/d. They include:
1. Use of monoamine oxidase inhibitors in the past 2 weeks
2. Glaucoma
3. Presence or history of marked agitation
4. History of drug abuse
5. Known hypersensitivity to sympathomimetic amines
6. Current use of selective serotonin re-uptake inhibitors (e.g., fluoxetine, sertraline,
etc)
7. Current use of any other weight loss medications (besides liraglutide 3.0 mg/d)
8. History of coronary artery disease
We found this trial at
1
site
Click here to add this to my saved trials
